CRNX (Crinetics Pharmaceuticals, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by CRNX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-01 | Weston Nichols | Director | D | — | — |
| 2026-09-01 | Coelho Rogerio Vivaldi | Director | D | — | — |
| 2026-09-01 | Isabel Kalofonos | Chief Commercial Officer | D | — | — |
| 2026-09-01 | Matthew K Fust | Director | D | — | — |
| 2026-09-01 | Tobin Schilke | Chief Financial & Infra. Ofcr. | D | — | — |
| 2026-09-01 | Richard Scott Struthers | President & CEO | D | — | — |
| 2026-09-01 | Camille L Bedrosian | Director | D | — | — |
| 2026-09-01 | WENDELL WIERENGA | Director | D | — | — |
| 2026-09-01 | Stephanie Okey | Director | D | — | — |
| 2026-09-01 | Stephen F. Betz | Chief Scientific Officer | D | — | — |
| 2026-09-01 | Caren Deardorf | Director | D | — | — |
| 2026-08-24 | Tobin Schilke | Chief Financial & Infra. Ofcr. | A | — | — |
| 2026-08-11 | Richard Scott Struthers | President & CEO | M | — | — |
| 2026-07-07 | Coelho Rogerio Vivaldi | Director | Sell | — | — |
| 2026-06-22 | Coelho Rogerio Vivaldi | Director | A | — | — |
| 2026-06-22 | Camille L Bedrosian | Director | A | — | — |
| 2026-06-22 | WENDELL WIERENGA | Director | A | — | — |
| 2026-06-22 | Caren Deardorf | Director | A | — | — |
| 2026-06-22 | Stephanie Okey | Director | A | — | — |
| 2026-06-22 | Matthew K Fust | Director | A | — | — |
| 2026-06-22 | Weston Nichols | Director | A | — | — |
| 2026-06-18 | Stephanie Okey | Director | Sell | — | — |
| 2026-06-02 | Richard Scott Struthers | President & CEO | G | — | — |
| 2026-04-10 | Jeff E. Knight | Chief Dev. & Operating Officer | MIXED | — | — |
| 2026-03-18 | Stephen F. Betz | Chief Scientific Officer | Sell | — | — |
| 2026-03-18 | Jeff E. Knight | Chief Operating Officer | Sell | — | — |
| 2026-03-18 | Richard Scott Struthers | President & CEO | Sell | — | — |
| 2026-03-13 | Coelho Rogerio Vivaldi | Director | Sell | — | — |
| 2026-03-04 | Stephanie Okey | Director | Sell | — | — |
| 2026-03-04 | Tobin Schilke | Chief Financial Officer | Sell | — | — |
| 2026-02-25 | Isabel Kalofonos | Chief Commercial Officer | A | — | — |
| 2026-02-25 | Stephen F. Betz | Chief Scientific Officer | A | — | — |
| 2026-02-25 | Richard Scott Struthers | President & CEO | A | — | — |
| 2026-02-25 | Jeff E. Knight | Chief Operating Officer | A | — | — |
| 2026-02-25 | Tobin Schilke | Chief Financial Officer | A | — | — |
| 2026-01-07 | Isabel Kalofonos | Chief Commercial Officer | MIXED | — | — |
| 2025-12-29 | Stephen F. Betz | Chief Scientific Officer | M | — | — |
| 2025-12-18 | Richard Scott Struthers | President & CEO | M | — | — |
| 2025-12-03 | Dana Pizzuti | Chief Med and Dev Officer | MIXED | — | — |
| 2025-11-05 | Dana Pizzuti | Chief Med and Dev Officer | MIXED | — | — |
| 2025-10-03 | Dana Pizzuti | Chief Med and Dev Officer | MIXED | — | — |
| 2025-09-30 | Richard Scott Struthers | President & CEO | Sell | — | — |
| 2025-09-30 | Matthew K Fust | Director | MIXED | — | — |
| 2025-09-04 | Dana Pizzuti | Chief Med and Dev Officer | MIXED | — | — |
| 2025-08-26 | Dana Pizzuti | Chief Med and Dev Officer | MIXED | — | — |
| 2025-08-21 | Dana Pizzuti | Chief Med and Dev Officer | Sell | — | — |
| 2025-06-16 | Stephen F. Betz | Chief Scientific Officer | MIXED | — | — |
| 2025-06-13 | Stephanie Okey | Director | A | — | — |
| 2025-06-13 | Matthew K Fust | Director | A | — | — |
| 2025-06-13 | Camille L Bedrosian | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 5,321,032 | — |
| — | 10%+ Owner | 3,659,381 | — |
| — | 10%+ Owner | 2,507,797 | — |
| — | 10%+ Owner | 2,458,445 | — |
| — | Director | 2,187,953 | — |
| — | 10%+ Owner | 376,785 | — |
| — | 10%+ Owner | 376,285 | — |
| — | 10%+ Owner | 298,625 | — |
| — | 10%+ Owner | 210,373 | — |
| — | Chief Dev. & Operating Officer | 190,452 | — |
| — | Chief Development Officer | 185,995 | — |
| — | CFO | 136,092 | — |
| — | 10%+ Owner | 129,483 | — |
| — | Director | 116,146 | — |
| — | — | 94,489 | — |
| — | Chief Med and Dev Officer | 66,837 | — |
| — | Chief Commercial Officer | 44,259 | — |
| — | Chief Medical Officer | 43,210 | — |
| — | Director | 5,925 | — |
| — | Director | 5,925 | — |
| — | Director | 5,925 | — |
| — | 10%+ Owner | 1,723 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CRNX quote page; the site-wide leaderboard is on the insider transactions hub.